Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 47 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

18 trials in Phase 3/4

Results Transparency

2 of 29 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

18(38.3%)

Phase 3

15(31.9%)

Phase 2

6(12.8%)

N/A

5(10.6%)

Phase 4

3(6.4%)

47Total

Phase 1(18)

Phase 3(15)

Phase 2(6)

N/A(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (47)

Showing 20 of 47 trials

NCT06824519Phase 1Recruiting

Clinical Trials of Quadrivalent Influenza Vaccine

Role: lead

NCT05899179Phase 3Completed

Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

Role: lead

NCT06747455Phase 3Active Not Recruiting

BCG for Therapeutic Use Phase Ⅲ Clinical Trial

Role: lead

NCT06100653Phase 1Completed

BCG for Therapeutic Use Phase I Clinical Trial

Role: lead

NCT06975774Phase 1Completed

Phase II Clinical Clical of the Pure Protein Derivatives of BCG

Role: lead

NCT06524947Phase 3Active Not Recruiting

Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Role: lead

NCT04538911Phase 1Active Not Recruiting

Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients

Role: lead

NCT04563533Phase 1Completed

Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Role: lead

NCT05746611Phase 4Completed

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Role: lead

NCT05574985Not ApplicableCompleted

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

Role: lead

NCT05680415Phase 4Active Not Recruiting

Clinical Trial of Mica

Role: lead

NCT05850507Not ApplicableCompleted

Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Role: lead

NCT05642078Phase 3Completed

Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Role: lead

NCT05284812Phase 2Suspended

A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Role: lead

NCT04852068Phase 3Unknown

A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)

Role: lead

NCT06078423Phase 3Completed

A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)

Role: lead

NCT06043388Phase 1Unknown

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

Role: lead

NCT05205096Phase 1Completed

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac

Role: lead

NCT06025812Not ApplicableUnknown

Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Role: lead

NCT05198063Phase 1Completed

ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization

Role: lead